10月 2026
ijbs.com
顯示 Similarweb 的估計資料。
透過連接你的 GA4 公開驗證你網站的指標
反映您的成功
連接 Google Analytics,認證您網站的流量和參與度指標
跳出率
47.17%
每次訪問頁數
2.13
平均訪問時長
00:00:50
- 公司介紹
- - -
- 行業
- - -
ijbs.com 的前十大競爭對手
在 10月 2026,系統根據關鍵字流量、受眾定位與市場重疊率與 ijbs.com 的相似程度,排名出 ijbs.com 等前 10 名網站。
Nature is the foremost international weekly scientific journal in the world and is the flagship journal for Nature Portfolio. It publishes the finest ...
- 公司介紹
- nature
跳出率
55.37%
每次訪問頁數
2.51
平均訪問時長
00:03:10
相似度評分
100%indexingmethod_automated - Search Results - PubMed
- 公司介紹
- - -
- 行業
- - -
全球排名
- -
國家/地區排名
- -
同類排名
- -
跳出率
- -
每次訪問頁數
- -
平均訪問時長
- -
sciencedirect is the world's leading source for scientific, technical, and medical research. explore journals, books and articles.
跳出率
31.28%
每次訪問頁數
6.01
平均訪問時長
00:07:55
providing access to millions of research articles and chapters from science, technology and medicine, and humanities and social sciences
- 公司介紹
- - -
- 行業
- - -
全球排名
- -
國家/地區排名
- -
同類排名
- -
跳出率
62.14%
每次訪問頁數
2.23
平均訪問時長
00:03:01
Cerebrospinal fluid–venous fistula is an increasingly recognized cause of spontaneous intracranial hypotension.[1][1] The site of the leak is between the dural sleeve around a spinal nerve root and the surrounding foraminal veins. In appropriately investigated patients, transvenous embolization of the draining foraminal and paraspinal veins has been shown to be an effective way of treating the disease, with low periprocedural morbidity, improvement in symptoms and radiological appearances.[2][2] [Video 1][3] shows the technique employed in a typical case using Onyx (Medtronic, Minnesota, USA) to embolize a CSF–venous fistula at the right T10 neural foramen. Video 1 Video showing the technique for trans-venous embolization of a right T10 CSF-venous fistula for the treatment of spontaneous intracranial hypotension. The first section covers patient selection and work up, before then focusing on the technical aspects of navigating through the azygos system to the target foramen and completely occluding the pathway for CSF outflow. [1]: #ref-1 [2]: #ref-2 [3]: #F1
- 公司介紹
- - -
- 行業
- - -
全球排名
- -
國家/地區排名
- -
同類排名
- -
跳出率
29.01%
每次訪問頁數
2.13
平均訪問時長
00:00:59
相似度評分
83%Radioimmunotherapy using 225Ac, a highly cytotoxic α-particle emitter, has potential for treating advanced breast cancer, especially human epidermal growth factor receptor 2 (HER2)–positive cases. We use a pretargeted radioimmunotherapy (PRIT) approach consisting of a 3-step intravenous regimen (step 1: bispecific anti-HER2/anti-DOTA antibody; step 2: clearing agent; step 3: 225Ac-radiolabeled Proteus DOTA, or [225Ac]Ac-Pr). Our goal was to establish curative 225Ac-PRIT with high therapeutic indices. Methods: The impact of [225Ac]Ac-Pr specific activity was evaluated in the BT-474 breast xenograft model. We tested the effects of [225Ac]Ac-Pr dosing during PRIT on tumor-targeting efficiency and tissue biodistribution. Using a 225Ac-PRIT regimen consisting of a ratio of 1.19 nmol of bispecific antibody to 0.60–0.66 nmol of [225Ac]Ac-Pr, we evaluated therapy in the BT-474 model and a patient-derived xenograft model. BT-474-tumor–bearing mice were treated with 1 or 2 cycles of 225Ac-PRIT (37 kBq/cycle) separated by 1 wk. A dose escalation study was performed on the BT-474 model to establish an absorbed radiation dose of approximately 40 Gy (relative biological effectiveness [RBE], 5) as a nephrotoxic dose, as no such histologic findings were observed in prior studies at the 20.7-Gy (RBE, 5) renal dose level. Results: In the BT-474 model, 100% (20/20) achieved complete responses and histologic cure in 17 of 20 (85%) of the treated animals. One-cycle and 2-cycle treatments were equally effective. Treatments were well tolerated, with no chronic radiation toxicity documented during necropsy at 175 d. Dosimetry estimates (RBE, 5) per 37 kBq administered for tumors and kidneys were 210 and 3.5 Gy, respectively. In the patient-derived xenograft model, a single 225Ac-PRIT treatment led to 60% (3/5) complete response and prolonged survival (>93 d) versus no treatment (30 d; P = 0.0185). Lastly, a 225Ac-PRIT regimen was identified that induces severe chronic nephrotoxicity (41.4
- 公司介紹
- - -
- 行業
- - -
全球排名
- -
國家/地區排名
- -
同類排名
- -
跳出率
56.36%
每次訪問頁數
2.04
平均訪問時長
00:01:23
- 公司介紹
- - -
- 行業
- - -
全球排名
- -
國家/地區排名
- -
同類排名
- -
跳出率
67.86%
每次訪問頁數
1.47
平均訪問時長
00:00:06
Discover and read the most cited articles from BMJ Quality & Safety published over the past two years.
- 公司介紹
- - -
- 行業
- - -
全球排名
- -
國家/地區排名
- -
同類排名
- -
跳出率
59.32%
每次訪問頁數
2.28
平均訪問時長
00:01:19
Oncology On the Go With ASTCT Talks | Podcasts | CancerNetwork is home to the journal Oncology & provides insights on the screening, early detection, diagnosis, treatment and prevention of cancers.
跳出率
45.98%
每次訪問頁數
1.59
平均訪問時長
00:00:35
- 公司介紹
- - -
- 行業
- - -
跳出率
52.85%
每次訪問頁數
1.56
平均訪問時長
00:00:48
ijbs.com 在 10月 2026的前 5 大競爭對手是:nature.com、pubmed.ncbi.nlm.nih.gov、sciencedirect.com、link.springer.com 等。
根據 Similarweb 月造訪量數據,ijbs.com 在 10月 2026 的主要競爭對手為 nature.com。與 ijbs.com 相似度排名第二的網站是 pubmed.ncbi.nlm.nih.gov,緊隨其後位居前三的是 sciencedirect.com。
在 10月 2026,link.springer.com 被評為與 ijbs.com 相似度第四高的網站,jnis.bmj.com 則位居第五。
前十名榜單中的其他五家競爭對手分別是 jnm.snmjournals.org、n.neurology.org、qualitysafety.bmj.com、cancernetwork.com 和 contemporaryobgyn.net。
